月湖免疫治疗

最新新闻

• 评级变动
  Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
  TipRanks · 2026/3/31
• LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/15
• TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)
  TipRanks · 2026/6/8
• 评级变动
  Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $70
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)
  TipRanks · 2026/6/9
• 评级变动
  H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/4/8
• Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/3/23
• 评级变动
  A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/6/9

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。